Improvement of the noradrenergic symptom cluster following treatment with milnacipran

Siegfried Kasper
Diana Meshkat
Alexandra Kutzelnigg

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

Abstract: Depression has a major impact on social functioning. Decreased concentration, mental and physical slowing, loss of energy, lassitude, tiredness, and reduced self-care are all symptoms related to reduced noradrenergic activity. Depressed mood; loss of interest or pleasure; sleep disturbances; and feelings of worthlessness, pessimism, and anxiety are related to reduced activity of both serotonergic and noradrenergic neurotransmission. The importance of noradrenergic neurotransmission in social functioning is supported by studies with the specific norepinephrine reuptake inhibitor reboxetine. In healthy volunteers, reboxetine increases cooperative social behavior and social drive. A placebo-controlled study in depressed patients comparing reboxetine with the selective serotonin reuptake inhibitor (SSRI) fluoxetine showed significantly greater improvement in social adaptation with reboxetine. Two recent studies have examined the effect of the serotonin and norepinephrine reuptake inhibitor milnacipran on social adaptation. A study in depressed patients found that at the end of 8 weeks of treatment with milnacipran, 42.2% patients were in remission on the Social Adaptation Self-evaluation Scale (SASS). Another study in depressed workers or homemakers found that mean depression scores were significantly reduced after 2 weeks, whereas the SASS scores were significantly improved after 4 weeks. A preliminary study comparing depressed patients treated with milnacipran or the SSRI paroxetine showed that milnacipran treatment resulted in a greater number of patients in social remission. The available data thus suggest that milnacipran may improve social functioning, with a possibly greater effect than the SSRI paroxetine. These preliminary data suggest further evaluation of social dysfunction and its treatment outcome in future trials of milnacipran.

Keywords: social functioning, Social Adaptation Self-evaluation Scale (SASS), depression, noradrenergic neurotransmission, serotonin and norepinephrine reuptake inhibitors (SNRIs), milnacipran

Introduction

The widespread disturbances of monoamine neurotransmission that occur in depression are probably fundamental to its pathophysiology. More specifically, a deficiency in serotonin (5-HT), norepinephrine (NE), and possibly dopamine (DA) neurotransmission has been suggested. A relationship exists between the different neurotransmitter deficits and the symptoms of major depression. Depressed mood; loss of interest or pleasure; sleep disturbances; and feeling of worthlessness, pessimism, and anxiety are symptoms related to changes in both 5-HT and NE neurotransmission. Agitation, loss of appetite, decreased libido, suicidal ideation, aggressive behavior (verbal or physical), and irritability are symptoms related principally to the dysfunction of 5-HT...
Noradrenergic symptom cluster and social dysfunction

The symptoms that are thought to be principally due to a deficit in noradrenergic transmission, the so-called noradrenergic symptom cluster, are those that result in social dysfunction (Figure 1). “Social dysfunction” is a collective term used to describe a variety of emotional problems experienced in social situations. It frequently leads to family disruption and social isolation. In the workplace it can lead to absenteeism and “presenteeism” (a term used to describe the lost productivity a worker experiences when he or she is able to attend work but is not performing optimally). Depression has a major negative impact on social functioning,10–14 which is possibly one of the most important factors affecting quality of life in depressed patients.

In the International Classification of Diseases, 10th Revision (ICD-10) and Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnostic criteria of major depression, the item “lack of interests or pleasure” only partly covers the concept of decreased social ability. However, in addition to the simple presence of certain symptoms, DSM-IV requires that the symptoms should cause significant distress or impairment in social, occupational, or other important areas of functioning.15

Improvement of social dysfunction during antidepressant treatment

Increasingly, the enhancement of social functioning is considered to be an important therapeutic target in the treatment of depression.15,16 Full recovery from depression thus requires not only the resolution of classical symptoms but also an improvement in the interaction of the individual with his or her environment.10,11,13 The ability to improve social functioning should legitimately influence the choice of antidepressant therapy.12

The measurement of social adaptation should therefore be an integral part of the assessment of the outcome of depressive episodes. A number of instruments have been developed to measure social functioning, each with certain advantages and disadvantages.17 Although several self- or clinician-evaluated social adjustment scales are available, they are frequently complex and time consuming, and their conceptual background is often poorly defined.18–20 The three most frequently used instruments for measuring social functioning are the 36-item Short-Form Health Survey,21 the Social Adjustment Scale Self-report,22 and the more recently developed Social Adaptation Self-evaluation Scale (SASS).18 It has been suggested17 that the SASS might be the most appropriate for studies exploring hypotheses about mechanisms involved in social dysfunction.

The importance of NE neurotransmission in social functioning is supported by studies using the specific NE reuptake inhibitor reboxetine. The effects of reboxetine have been studied in healthy volunteers using a stranger-dyadic social interaction paradigm and cooperative game situations,22–24 where it was found to increase cooperative social behavior and social drive, making participants more self-confident and assertive. In contrast, the selective serotonin reuptake inhibitor (SSRI) citalopram had significantly less effect on cooperative behavior.22

Because depression causes extensive social dysfunction, antidepressant treatment would be expected to lead to improved social functioning. An early study25 found that social and interpersonal maladjustments occurring in depressed women improved with antidepressant treatment during 8-month follow-up. The considerable improvement in social adjustment, however, occurred more slowly than for other symptoms. Symptomatic relapse was accompanied by rapid social worsening.25

The first double-blind, placebo-controlled study to use the SASS showed that 8 weeks of treatment with reboxetine (8 mg/d) resulted in a significantly greater improvement in social functioning compared with patients treated with the SSRI fluoxetine (20 mg/d) or with placebo (Figure 2).26,27 Another study28 comparing the effects of reboxetine (8–10 mg/d) and fluoxetine (20–40 mg/d) over 8 weeks found that both antidepressants improved the scores on the Hamilton Depression Rating Scale (HDRS) to a similar

**Figure 1** The noradrenergic symptom cluster and social dysfunction. The components of the noradrenergic symptom cluster are closely linked to social dysfunction. “Presenteeism” is a term used to describe the lost productivity a worker experiences when he or she is able to attend work but is not performing optimally.
extent. In patients who achieved remission from their depressive symptoms, however, social dysfunction was improved to a significantly greater extent by patients taking reboxetine compared with fluoxetine (Figure 2).

These studies suggest that antidepressants with an important noradrenergic component, such as reboxetine, may be particularly effective in improving social functioning.29 If improved social adaptation is related to increased NE activity, then serotonin and norepinephrine reuptake inhibitors (SNRIs) should be particularly effective in reducing social dysfunction in depressed patients.

There have been relatively few studies of SNRIs investigating their effects on social adaptation. A small study30 that compared treatment of depressed patients with venlafaxine and amitriptyline found the two drugs to be equally effective in relieving depressive symptoms. Venlafaxine-treated patients showed a significantly greater improvement in social adjustment. An open-label case study of five patients with treatment-resistant severe depression31 found that treatment with high-dose (450–600 mg/d) venlafaxine resulted in an improvement in depressive symptoms (>50% decrease in baseline HDRS scores) in four patients. Social adjustment scores of two of these patients were normalized by the end of the study. An open-label study of 26 patients suffering from seasonal affective disorder (SAD)32 treated with duloxetine (60–120 mg/d) for 8 weeks showed that both SAD and social adaptation were improved. The studies with milnacipran are discussed at the end of the next section.

**Milnacipran: the most noradrenergic SNRI**

Of the four SNRIs currently available, milnacipran is the most noradrenergic in terms of its selectivity for the inhibition of the reuptake of NE and 5-HT (Figure 3).33,34 There is neurochemical and neurophysiological evidence that milnacipran acts by increasing NE neurotransmission. A study investigating the influence of NE transporter polymorphism (NET-T182C polymorphism) on the antidepressant effect of milnacipran35 found a significant difference ($P < 0.03$) in response, depending on the genotype of the patients (T/T 76.7% responders; T/C 57.8% responders; C/C 20% responders). Similarly, antidepressant response with milnacipran was sensitive to NET-G1287A polymorphism, with the A/A genotype being associated with a slower onset of therapeutic response.33

![SASS score improvement in all patients (8-week study) and in remission (4-week study)](image_url)

Figure 3 Visual representation of the selectivity for serotonin (5-HT) and norepinephrine (NE) transporter in vitro. The light gray segments represent the relative affinity for the 5-HT transporter, and the dark gray segments represent the relative affinity for the NE transporter. Calculated from data in reference 33.
In contrast, there was no influence of 5-HTT polymorphisms on the antidepressant response to milnacipran. These results suggest that the effect of milnacipran on the NE transporter is fundamental to its action.

The effects of milnacipran on the noradrenergic symptom cluster
Concentration
The effect of milnacipran has been specifically studied on certain symptoms of the noradrenergic symptom cluster. The critical flicker fusion (CFF) task evaluates the integrative capacity of the brain and the ability to discriminate discrete quanta of sensory information. The CFF is sensitive to psychoactive drugs, and a decrease in CFF threshold indicates decreased cognitive capacity. In a study of elderly (>65 years) healthy volunteers in whom amitriptyline (50 mg/d for 3 days) significantly decreased CFF, milnacipran (75 mg/d for 3 days) caused a small but significant increase in CFF, indicating a small enhancement of cognitive capacity.

Retardation
The HDRS defines “retardation” in item 8 as slowness of thought and speech, impaired ability to concentrate, and decreased motor activity, and rates it on a 0–4 scale. A subanalysis of data from a study comparing milnacipran (100 mg/d) with paroxetine (20 mg/d) examined item 8 of the HDRS in comparison with response on the Clinical Global Improvement (CGI) scale. Patients with low levels of retardation (score 0 or 1) had similar response rates on milnacipran and paroxetine. Patients with high levels of retardation (score 3 or 4), however, responded significantly better to milnacipran than to paroxetine (Figure 4).

Tiredness
Milnacipran has not been investigated extensively in sleep disorders, but in various studies milnacipran has been noted to improve disturbed sleep patterns by decreasing sleep latency and nocturnal awakenings and increasing the latency of rapid eye movement sleep. This improvement in sleep is likely to go some way to improving tiredness.

The effects of milnacipran on social dysfunction
Two recent studies have examined the effect of milnacipran on social adaptation as measured by the SASS. Both have been published exclusively in Japanese but have been presented and discussed in detail in a recent review.

In one study, milnacipran was administered at 50 mg/d, increasing to 100 mg/d (mean final dose 83.7 mg/d) to 45 patients with major depressive disorder for 8 weeks. Significant improvement in the classical symptoms of depression, as measured by HDRS and Beck Depression Inventory (BDI), was observed after 2 weeks, and significant improvement of social dysfunction (SASS) after 4 weeks (Figure 5). After 8 weeks of treatment, 51.1% patients were in remission for depression (HDRS < 7) and 42.2% for social dysfunction (SASS > 35). Nonresponders on the HDRS had no significant improvement in their SASS score at endpoint. There was a significant negative correlation (P < 0.01) between the reduction in HDRS score from baseline to endpoint and the increase in SASS score from baseline to endpoint.
The second study\textsuperscript{45} included 113 patients, employees, or homemakers with major depressive episodes. Milnacipran was administered at 25–50 mg/d, increasing to 100 mg/d by 2 weeks, and then continuing at this dose for 8 weeks (average final dose 85.4 mg/d). Mean HDRS and Zung Self-rating Depression Scale (SDS) scores were significantly reduced ($P < 0.01$) from 2 weeks, whereas the SASS was only significantly increased ($P < 0.01$) from 4 weeks. At endpoint, 67.4\% patients were classified as responders (\(\geq 50\%\) reduction of baseline HDRS), and 43.0\% were in remission (HDRS \(\leq 7\)); 33.3\% patients had remission on SASS (\(\geq 35\) points). There was a significant negative correlation between $\Delta$SASS (baseline to endpoint difference) and $\Delta$HDRS ($-0.39 P < 0.01$), although the correlation was considerably weaker than between the two depression scales ($\Delta$HDRS and $\Delta$SDS; 0.74 $P < 0.01$).

Both studies showed significant improvement on the SASS scale from 4 weeks of treatment, whereas a significant improvement on depression scales occurred by 2 weeks. Both studies reported a significant negative correlation between changes in the SASS and changes in the HDRS. This correlation was, however, weaker than that between two depression rating scales. Globally, these data suggest that improvement in social function, as measured by the SASS, may be more difficult and slower to achieve than improvement in classical depressive symptoms.

A recent review of the effect of SNRIs on social function\textsuperscript{43} mentions an unpublished study that compares the improvement of social function in depressed patients treated with milnacipran (mean dose 83 mg/d) and paroxetine (mean dose 35 mg/d). Milnacipran treatment resulted in a greater number of patients with social remission than treatment with paroxetine.

**Conclusion**

The symptoms that constitute the noradrenergic symptom cluster are those that play an important role in social dysfunction. There is a suggestion that antidepressants activating NE neurotransmission may improve social functioning more rapidly and/or to a greater extent than those acting exclusively on 5-HT function.\textsuperscript{43} The efficacy of reboxetine in the recovery of social function compared with SSRIs is compatible with the importance of noradrenergic deficit in social dysfunction. If this is indeed true, SNRIs would also be expected to be particularly effective in improving social functioning.

Milnacipran is the most noradrenergic SNRI in terms of its selectivity for the NE transporter and 5-HT transporter. It has been shown to have positive effects on concentration and retardation. This latter effect has been shown to be significantly greater than with paroxetine. Among the SNRIs, milnacipran might therefore be expected to be particularly effective in reducing social dysfunction associated with depression. Evidence, which is still incomplete, suggests that milnacipran may improve social function in depressed patients. Although the effects on depressive symptoms and social dysfunction are correlated, improvement in social function appears to have a slower time course than improvement of other depressive symptoms.

The studies that are currently available are all small, and many of them are not comparative. This is a clear limitation of support for the hypothesis. Although there is a first indication that milnacipran may possibly produce a greater improvement of social function than paroxetine, the question is still open. Clearly, the studies need to be replicated in a controlled and comparative environment. In addition, the interesting question of the potential positive interaction between psychotherapy and pharmacotherapy in the improvement of social function needs to be addressed.

Social dysfunction is one of the most important factors affecting quality of life of depressed patients, and it is possibly of even greater importance in the treatment of elderly patients suffering from major depression. For the patient to recover fully from the effects of depression, it is important to have not only full and sustained relief from the classical symptoms of depression but also a complete recovery of the ability to interact with friends and other individuals in the family and work environment. The enhancement of social functioning should thus be considered a major therapeutic goal in the management of depression.

**Acknowledgment**

The author would like to thank Dr Mike Briley for his editorial help in the preparation of this manuscript.

**Disclosure**

Dr Kasper has received grant/research support from Eli Lilly, Lundbeck, Bristol-Myers Squibb, GlaxoSmithKline, Organon, Sepracor, and Servier; has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Lundbeck, Pfizer, Organon, Schwabe, Sepracor, Servier, Janssen, and Novartis; and has served on speakers’ bureaus for AstraZeneca, Eli Lilly, Lundbeck, Schwabe, Sepracor, Servier, Pierre Fabre, and Janssen. Dr Kutzelnigg has received travel grants from Eli Lilly and Affiris AG and payment for lectures including...
service on speakers’ bureaus from Eli Lilly, Novartis, and Affiris AG. Dr. Meshkat received a travel grant from Affiris.

References